A fast and accurate mouse model for inducing non-alcoholic steatohepatitis
Gastroenterology and Hepatology from Bed to Bench,
Aim: This study aimed to perform a head-to-head comparison of changes during NASH progression throughout 6-11 weeks of an experiment to supply a faster nutritional model in mimicking NASH to decrease the duration and cost of in vivo studies.
Background: New therapies are urgently needed because of the growing prevalence of non-alcoholic steatohepatitis (NASH) and the lack of an effective treatment approach. Currently, dietary interventions are the most efficient options.
Methods: This study compared features of NASH in a murine model using protocol that combined special nutritional regimes based on the combination of 21.1% fat, 41% sucrose, and 1.25% cholesterol with weekly intraperitoneal injections of carbon tetrachloride (CCl4). Male C57BL/6J mice received either special compositions + CCl4 (NASH group) or standard chow diet (healthy control group) for 11 weeks. Liver histopathology based on hematoxylin and eosin (H&E) and Masson’s Trichrome (TC) staining and biochemical analyses were used to assess disease progression.
Results: In C57BL/6J mice administered a high fat, high cholesterol, high sucrose diet and CCl4 for 8 weeks, steatohepatitis with pronounced hepatocyte ballooning, inflammation, steatosis, and fibrosis was observed. According to the NAFLD activity scoring system, the maximum NAS score was manifested after 8-9 weeks (NAS score: 6.75). Following this protocol also led to a significant increase in AST and ALT, total cholesterol, and total triglyceride serum levels in the NASH group.
Conclusion: Following the special nutritional regime based on high fat, cholesterol, and sucrose in combination with CCL4 injections resulted in a NASH model using C57BL/6J mice in a shorter time compared to similar studies. The obtained histopathological NASH features can be advantageous for preclinical drug testing.
- Nonalcoholic Steatohepatitis, Animal model, Liver Diseases, Carbon Tetrachloride
How to Cite
Dufour J-F, Scherer R, Balp M-M, et al. The global epidemiology of nonalcoholic steatohepatitis (NASH) and associated risk factors–A targeted literature review. Endocr Metab Sci 2021;3:100089.
Sheka AC, Adeyi O, Thompson J, et al. Nonalcoholic steatohepatitis: a review. Jama 2020;323:1175-1183.
Abdelmalek MF. Nonalcoholic fatty liver disease: another leap forward. Nat Rev Gastroenterol Hepatol 2021;18:85-86.
Thrasher T, Abdelmalek MF. Nonalcoholic fatty liver disease. N C Med J 2016;77:216-219.
Dufour JF, Caussy C, Loomba R. Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges. Gut 2020;69:1877-1884.
Geier A, Rau M. Emerging therapies for NASH - the future is now. Expert Rev Clin Pharmacol 2017;10:467-469.
Campbell P, Symonds A, Barritt ASt. Therapy for nonalcoholic fatty liver disease: current options and future directions. Clin Ther 2021;43:500-517.
Soret PA, Magusto J, Housset C, et al. In vitro and in vivo models of non-alcoholic fatty liver disease: a critical appraisal. J Clin Med 2020;10.
Carreres L, Jílková ZM, Vial G, et al. Modeling diet-induced NAFLD and NASH in rats: a comprehensive review. Biomedicines 2021;9:378.
Nakamura A, Tajima K, Zolzaya K, et al. Protection from non-alcoholic steatohepatitis and liver tumourigenesis in high fat-fed insulin receptor substrate-1-knockout mice despite insulin resistance. Diabetologia 2012;55:3382-91.
Kohli R, Kirby M, Xanthakos SA, et al. High-fructose, medium chain trans fat diet induces liver fibrosis and elevates plasma coenzyme Q9 in a novel murine model of obesity and nonalcoholic steatohepatitis. Hepatology 2010;52:934-44.
Machado MV, Michelotti GA, Xie G, et al. Mouse models of diet-induced nonalcoholic steatohepatitis reproduce the heterogeneity of the human disease. PLoS One 2015;10:0127991.
Itagaki H, Shimizu K, Morikawa S, et al. Morphological and functional characterization of non-alcoholic fatty liver disease induced by a methionine-choline-deficient diet in C57BL/6 mice. Int J Clin Exp Pathol 2013;6:2683-96.
Stephenson K, Kennedy L, Hargrove L, et al. Updates on dietary models of nonalcoholic fatty liver disease: current studies and insights. Gene Expr 2018;18:5-17.
Marques TG, Chaib E, da Fonseca JH, et al. Review of experimental models for inducing hepatic cirrhosis by bile duct ligation and carbon tetrachloride injection. Acta Cir Bras 2012;27:589-94.
Liedtke C, Luedde T, Sauerbruch T, et al. Experimental liver fibrosis research: update on animal models, legal issues and translational aspects. Fibrogenesis Tissue Repair 2013;6:19.
Scholten D, Trebicka J, Liedtke C, et al. The carbon tetrachloride model in mice. Lab Anim 2015;49:4-11.
Kubota N, Kado S, Kano M, et al. A high-fat diet and multiple administration of carbon tetrachloride induces liver injury and pathological features associated with non-alcoholic steatohepatitis in mice. Clin Exp Pharmacol Physiol 2013;40:422-30.
Tsuchida T, Lee YA, Fujiwara N, et al. A simple diet- and chemical-induced murine NASH model with rapid progression of steatohepatitis, fibrosis and liver cancer. J Hepatol 2018;69:385-395.
Hansen HH, Feigh M, Veidal SS, et al. Mouse models of nonalcoholic steatohepatitis in preclinical drug development. Drug Discov Today 2017;22:1707-1718.
Savari F, Mard SA, Badavi M, et al. A new method to induce nonalcoholic steatohepatitis (NASH) in mice. BMC Gastroenterol 2019;19:125.
Liang W, Menke AL, Driessen A, et al. Establishment of a general NAFLD scoring system for rodent models and comparison to human liver pathology. PLoS One 2014;9:115922.
Xu G, Ye J, Liu X-J, et al. Activation of pluripotent genes in hepatic progenitor cells in the transition of nonalcoholic steatohepatitis to pre-malignant lesions. Lab Invest 2017;97:1201-1217.
Iqbal U, Perumpail BJ, Akhtar D, et al. The epidemiology, risk profiling and diagnostic challenges of nonalcoholic fatty liver disease. Medicines 2019;6.
Giannini EG, Testa R, Savarino V. Liver enzyme alteration: a guide for clinicians. Cmaj 2005;172:367-79.
Kim WR, Flamm SL, Di Bisceglie AM, et al. Serum activity of alanine aminotransferase (ALT) as an indicator of health and disease. Hepatology 2008;47:1363-70.
Farrell GC, van Rooyen D. Liver cholesterol: is it playing possum in NASH? Am J Physiol Gastrointest Liver Physiol 2012;303:9-11.
Diehl AM, Day C. Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis. N Engl J Med 2017;377:2063-2072.
Ibrahim SH, Hirsova P, Malhi H, et al. Animal models of nonalcoholic steatohepatitis: eat, delete, and inflame. Dig Dis Sci 2016;61:1325-36.
Hansen HH, Feigh M, Veidal SS, et al. Mouse models of nonalcoholic steatohepatitis in preclinical drug development. Drug Discovery Today 2017;22:1707-1718.
Liu XJ, Duan NN, Liu C, et al. Characterization of a murine nonalcoholic steatohepatitis model induced by high fat high calorie diet plus fructose and glucose in drinking water. Lab Invest 2018;98:1184-1199.
Charlton M, Krishnan A, Viker K, et al. Fast food diet mouse: novel small animal model of NASH with ballooning, progressive fibrosis, and high physiological fidelity to the human condition. Am J Physiol Gastrointest Liver Physiol 2011;301:825-34.
Asgharpour A, Cazanave SC, Pacana T, et al. A diet-induced animal model of non-alcoholic fatty liver disease and hepatocellular cancer. J Hepatol 2016;65:579-588.
Clapper JR, Hendricks MD, Gu G, et al. Diet-induced mouse model of fatty liver disease and nonalcoholic steatohepatitis reflecting clinical disease progression and methods of assessment. Am J Physiol Gastrointest Liver Physiol 2013;305:483-95.
Dowman JK, Hopkins LJ, Reynolds GM, et al. Development of hepatocellular carcinoma in a murine model of nonalcoholic steatohepatitis induced by use of a high-fat/fructose diet and sedentary lifestyle. Am J Pathol 2014;184:1550-1561.
Urtasun R, Lopategi A, George J, et al. Osteopontin, an oxidant stress sensitive cytokine, up-regulates collagen-I via integrin α(V)β(3) engagement and PI3K/pAkt/NFκB signaling. Hepatology 2012;55:594-608.
Eng JM, Estall JL. Diet-induced models of non-alcoholic fatty liver disease: food for thought on sugar, fat, and cholesterol. Cell 2021;10.
Chheda TK, Shivakumar P, Sadasivan SK, et al. Fast food diet with CCl4 micro-dose induced hepatic-fibrosis--a novel animal model. BMC Gastroenterol 2014;14:89.
Rosada M, Wasityastuti W, Pratama YY, et al. The effects of high-fat diet and CCl₄ administration on liver function and lipid profile in non-alcoholic fatty liver disease rat model, in 7th International Conference on Biological Science (ICBS 2021), Atlantis Press, 2022.
Marcher A-B, Bendixen SM, Terkelsen MK, et al. Transcriptional regulation of hepatic stellate cell activation in NASH. Sci Rep 2019;9:2324-2324.
Peng C, Stewart AG, Woodman OL, et al. Non-alcoholic steatohepatitis: a review of its mechanism, models and medical treatments. Front Pharmacol 2020;11.
Ito M, Suzuki J, Tsujioka S, et al. Longitudinal analysis of murine steatohepatitis model induced by chronic exposure to high-fat diet. Hepatol Res 2007;37:50-7.
Van Rooyen DM, Gan LT, Yeh MM, et al. Pharmacological cholesterol lowering reverses fibrotic NASH in obese, diabetic mice with metabolic syndrome. J Hepatol 2013;59:144-52.
Bieghs V, Van Gorp PJ, Wouters K, et al. LDL receptor knock-out mice are a physiological model particularly vulnerable to study the onset of inflammation in non-alcoholic fatty liver disease. PLoS One 2012;7:30668.
- Abstract Viewed: 0 times